semaglutide addiction treatment as a promising new for alcohol use disorder Annette Lawless | A medication

That shows the independent action of IGF-1 in addition to its mediating properties of HGH

Clinical trials have demonstrated that it can reduce the risk of major adverse cardiovascular events in people with type 2 diabetes

Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication

However, its best to introduce one at a time to monitor effects